[17, 26, 27] |
Potentiate CD40L stimulation of DCs |
[2, 28–32] |
[17, 33] |
Potentiate CD8 T-cell stimulation by DCs |
[34] |
[17, 21, 33] |
Potentiate IFN-γ production, by cocultured T cells |
[17, 21, 33] |
[17, 26, 27, 32, 35] |
Potentiate IL-12p70 and IL-6 production, by DCs |
[17, 26, 27, 32, 35] |
[17, 21] |
Potentiate CCR7-driven migration of DCs (controversial) |
[24, 25, 32, 36, 37] |
[17, 38, 39] |
Induce CD38 in DCs |
[28, 40] |
[26, 27, 35, 41, 42] |
Stimulate production of CXCL9 and CXCL10 by DCs |
[24, 25, 43] |
[8, 44–48] |
Can block APC capacity of DCs (via expression of B7-H1 and IDO by DCs) |
[49] |
[8, 50] |
Potentiate IL-27 production by DCs, reduce OPN |
[2, 28, 51–58] |
[17, 26, 27] |
Upregulate MHC class I (and II) molecules in DCs |
[59, 60] |
[61–64] |
Increase IL-15 production and transpresentation by DCs |
[61, 62, 65–70] |
To be tested |
Increase T and NK cells activation and maintenance |
[60] |
Frasca and Lande, unpublished |
Induce CD70 upregulation on DCs |
Frasca and Lande, unpublished [63, 71] |